HGEN News and Press, Humanigen Inc. From 04/19/22

In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to standard of care (SOC) could result in over £5.5 million in cost savings weekly 1 Lenzilumab plus SOC resulted in per‑patient cost savings between £8,462 and £17,277 (net s...

The following slide deck was published by Humanigen, Inc. in conjunction with this event. For further details see: Humanigen (HGEN) April 2022 IR Presentation - Slideshow

About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...

Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long CO...

The following slide deck was published by Humanigen, Inc. in conjunction with this event. For further details see: Humanigen (HGEN) Presents at the ROTH 34th Annual Conference 2022 - Slideshow

Given the breakdown in the stock market this year, some of the “cutting edge” industries have taken it on the chin. But few have dropped as much as biotech has in 2022. But, as with most growth stocks, the latest bull market trend has given a nice boost to some of these names,...

The shares of clinical-stage biotech, Humanigen (HGEN +13%) Chief Scientific Officer Dale Chappell bought 1M shares in multiple transactions for $3 worth ~$3M. Post these transactions, the officer owns 7.9M shares. On March 11, the company gained the most in nearly a year on Ch...

If you’re looking for penny stocks to buy, you’re not alone. But with the latest global unrest sparking massive volatility in the stock market, it’s easier said than done. Identifying clear trends has been tougher, thanks to these wild swings. However, it isn’t i...

The shares of clinical-stage biotech, Humanigen (HGEN +22.1%), have added more than a fifth on Friday to record the biggest intraday gain since March 2021, after the company’s Chief Scientific Officer, Dale Chappell, disclosed a series of insider purchases. In a regulatory filing on Th...

Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%.  ...